The test was made about 10 times more sensitive than standard rapid immunoassays by tweaking a number of the firm's proprietary technologies, a company official said.
The firm's SteriPath device can reduce contamination tenfold, and it has hired a new chief commercialization officer to expand its reach in the preanalytical diagnostics space.
